Literature DB >> 3382590

N-acetylation polymorphism of dapsone in a Japanese population.

Y Horai1, T Ishizaki.   

Abstract

1. The N-acetylation of dapsone (DDS) was studied in 182 unrelated healthy Japanese subjects. The frequency of slow acetylators determined using the plasma monoacetyldapsone (MADDS) to DDS ratio (MADDS/DDS, slow acetylators less than 0.30 and rapid acetylators greater than 0.35) at 3 h after an oral dose of DDS (100 mg) was 6.6% (12 of the 182 subjects) with a 95% confidence interval of 3.8 to 11.2%. 2. The frequency distribution histogram of the plasma MADDS/DDS ratio showed an apparent trimodal pattern. However, the numbers of heterozygous (n = 105) and homozygous rapid acetylators (n = 65) derived from the observed data did not agree with those predicted for the respective rapid acetylators (n = 70, and n = 100) by applying the Hardy-Weinberg Law, when the suggested antimode of 0.85 discriminating these two rapid acetylators was employed. 3. The incidence of slow acetylators was unexpectedly lower in the males (1.4%, 1 of the 69 subjects, with a 95% confidence interval of 0.2 to 7.7%) compared with the incidence in the females (9.7%, 11 of the 113 subjects, with a 95% confidence interval of 5.5 to 16.6%). The difference reached a marginally significant level (Fisher's exact probability test, P = 0.02). 4. The mean plasma concentration of MADDS was significantly (P less than 0.001) lower in the slow compared to the rapid acetylators and there was a highly significant correlation (rs = 0.757, P less than 0.001) between plasma MADDS levels and MADDS/DDS ratios. 5. Slow acetylators showed a significantly (P less than 0.001) lower urinary MADDS/DDS ratio and excreted less (P less than 0.001) MADDS than rapid acetylators.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3382590      PMCID: PMC1387811          DOI: 10.1111/j.1365-2125.1988.tb03333.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  29 in total

1.  Genetic control of isoniazid metabolism in man.

Authors:  D A EVANS; K A MANLEY; V A McKUSICK
Journal:  Br Med J       Date:  1960-08-13

Review 2.  Disease and acetylation polymorphism.

Authors:  P K Lunde; K Frislid; V Hansteen
Journal:  Clin Pharmacokinet       Date:  1977 May-Jun       Impact factor: 6.447

3.  The polymorphic acetylation of dapsone in man.

Authors:  R Gelber; J H Peters; G R Gordon; A J Glazko; L Levy
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

4.  Kinetic discrimination of three sulfamethazine acetylation phenotypes.

Authors:  D J Chapron; P A Kramer; S A Mercik
Journal:  Clin Pharmacol Ther       Date:  1980-01       Impact factor: 6.875

5.  Acetylator phenotyping: a comparison of the isoniazid and dapsone tests.

Authors:  A Hanson; A Melander; E Wåhlin-Boll
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

6.  Clinical consequences of polymorphic acetylation of basic drugs.

Authors:  D E Drayer; M M Reidenberg
Journal:  Clin Pharmacol Ther       Date:  1977-09       Impact factor: 6.875

7.  Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype.

Authors:  K Carr; J A Oates; A S Nies; R L Woosley
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

8.  Plasma and salivary pharmacokinetics of dapsone estimated by a thin layer chromatographic method.

Authors:  R A Ahmad; H J Rogers
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

9.  Isoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects.

Authors:  Y Horai; T Ishizaki; T Sasaki; G Koya; K Matsuyama; S Iguchi
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

10.  Dapsone in saliva and plasma of man.

Authors:  J H Peters; J F Murray; G R Gordon; R H Gelber
Journal:  Pharmacology       Date:  1981       Impact factor: 2.547

View more
  7 in total

Review 1.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 2.  Interethnic differences in pharmacokinetics of antibacterials.

Authors:  Danny Tsai; Janattul-Ain Jamal; Joshua S Davis; Jeffrey Lipman; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

3.  Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer.

Authors:  Y Horai; K Fujita; T Ishizaki
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 4.  Drug acetylation in liver disease.

Authors:  M Levy; Y Caraco; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1998-03       Impact factor: 6.447

5.  Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations.

Authors:  D R Sohn; S G Shin; C W Park; M Kusaka; K Chiba; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

6.  N-acetylation phenotyping using dapsone in a Jordanian population.

Authors:  Y M Irshaid; H F al-Hadidi; M A Abuirjeie; N M Rawashdeh
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

7.  N-acetyltransferase activity in the urine in Japanese subjects: comparison in healthy persons and bladder cancer patients.

Authors:  S Ishizu; C Hashida; T Hanaoka; K Maeda; Y Ohishi
Journal:  Jpn J Cancer Res       Date:  1995-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.